Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 13 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum EU Excise Duty Rates on Tobacco Products in its Response to the Public... MOST POPULAR Update Shows Long-Term Survival Benefit with Abemaciclib Plus Fulvestrant in HR-positive,... November 21, 2020 Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans July 31, 2019 Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III... September 11, 2020 Cancer vaccines – where are we? February 24, 2023 Load more HOT NEWS Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed... Motivational Speaker Shares Her 11-Year Battle With Breast Cancer In New... Advancing Cancer Prevention: A Conversation with NCI’s Dr. Philip Castle Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin...
